<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ870831-0019 </DOCNO><HL> Business Brief:Duramed Pharmaceuticals Inc.</HL><DD> 08/31/87</DD><SO> WALL STREET JOURNAL (J)</SO><IN> DRMD </IN><TEXT>   Duramed Pharmaceuticals Inc., Cincinnati, said it expects to report a loss for the third quarter, as a result of lower-than-expected shipments.    The maker and seller of generic drug products had 1986 third-quarter net income of $417,455, or 21 cents a share, after a onetime gain of $192,000, or 10 cents a share, from a tax-loss carry-forward, on sales of $4.2 million.    Separately, Duramed said its registration statement covering 556,475 shares of common stock related to stock options outstanding became effective last Wednesday. These options relate to a 1984 research-and-development limited partnership agreement between the company and Duramed Research Associates. </TEXT></DOC>